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P E R S P E C T I V E S
Could Inflammaging and Its Sequelae Be Prevented
or Mitigated?
This article was published in the following Dove Press journal:
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Abstract: Aged humans display a chronic and low-grade inflammation, termed “inflamma-
ging”, which has been potentially linked to the subsequent development of some aging-
associated systemic disorders, including type 2 diabetes, atherosclerotic cardiovascular disease,
Alzheimer’s disease and obesity. Though the origin of aging-associated systemic inflammation is
uncertain, epidemiological studies show that inflammatory dermatoses (psoriasis and eczema)
are risk factors for some aging-associated systemic disorders, such as type 2 diabetes and
atherosclerotic cardiovascular disease. Moreover, recent studies demonstrate that epidermal
dysfunction in aged skin not only causes cutaneous inflammation, but also a subsequent increase
in circulating levels of proinflammatory cytokines, suggesting that the skin could be a major
contributor to inflammaging. This hypothesis is further supported by reductions in circulating
levels of proinflammatory cytokines in both aged humans and murine, following improvements
in epidermal function with topical emollients. Therefore, correction of epidermal dysfunction
could be a novel approach for the prevention and mitigation of certain inflammation-associated
chronic disorders in aged humans.
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As humans age, they almost inevitably suffer from one or more disorders associated
with chronological aging, including type 2 diabetes, atherosclerotic cardiovascular
disease, Alzheimer’s disease, obesity, osteoporosis, and sarcopenia. While the patho-
genesis of these chronic aging-associated disorders is still poorly understood, increas-
ing evidence points to a provocative role of sustained, sub-clinical inflammation,
often termed “inflammaging,” in the development of these chronic disorders.1–7 In
support of this notion, chronologically aged humans (≥50 years) display elevated
circulating levels of pro-inflammatory cytokines, particularly IL-6, IL-1β and TNFα.
Moreover, subjects with chronic cutaneous inflammatory diseases, such as psoriasis
and eczematous dermatitis, also display an increased prevalence of aging-associated
disorders, including atherosclerotic cardiovascular disease, obesity and type 2
diabetes.8 Though anti-inflammatory regimens, such as inhibitors of IL-1βα and
TNFα, as well as methotrexate, have been deployed in the management of these
aging-associated disorders, the outcomes of treatments with these agents have been
inconclusive.9 It is possible that the effective, pathogenesis-based preventive regi-
mens remain unavailable, in large part, because of the uncertainty of the pathogenesis
of “inflammaging”.
While many chronologically aged humans merely display marked evidence of
inflammation, they nonetheless display elevated circulating levels of cytokines, suggest-
ing that one or more, as yet identified organs, could account for the aging-associated
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increase in circulating cytokines. It seems reasonable to pos-
tulate that the responsible organ(s) must be large enough to
sustain such an increase in circulating cytokines, even without
noticeable inflammation. Although the musculoskeletal sys-
tem is the largest organ in humans, most chronologically aged
humans display no evidence ofmusculoskeletal inflammation.
Other relatively large organs to be considered include the skin,
intestines, lungs and liver. The skin, with a surface area of
≈1.5–2.0 m2, weighs about 20 lbs (with an additional, variable
contribution from subcutaneous adipose tissues), while the
weights of the intestines (surface area≈250 m2), lungs
(surface≈50–75m2) and liver represent ≈7.5, 5.0 and 3.3 lbs,
respectively. Because of their relatively lesser size, inflamma-
tion of the lungs, intestines and liver likely would not only
need to be apparent, but also sustained if any of these organs
could account for the increase in circulating levels of cyto-
kines. Yet again, the majority of otherwise normal aged
humans display few clinical signs or symptoms of inflamma-
tion in these organs. Hence, it seems unlikely that they could
contribute substantially to “inflammaging” unless multiple
organs simultaneously exhibit mild inflammation. Notably,
the aged skin commonly exhibits signs and symptoms of
inflammation, such as pruritus and senile xerosis.10–12
Because of its relatively large size, we hypothesized that
the skin could be an important contributor to the elevated
levels of circulating cytokines in chronologically aged
humans, despite the fact that it typically displays little
evidence of inflammation. Not only its size, but also its
unique anatomic site, serving as the interface between the
body and external environment, supports our hypothesis. In
this site, it is continuously exposed to external physical and
chemical stressors, which themselves can provoke inflam-
mation, even as other less-exposed organs remain quies-
cent. In addition, chronologically aged humans display
alterations in several key epidermal functions, each of
which can provoke low-grade, chronic inflammation in the
skin. For example, otherwise normal, chronologically aged
humans display lower levels of stratum corneum hydration,
as early as age ≈45 years, resulting in an increase in cuta-
neous cytokine production.10,13,14 Moreover, skin surface
pH increases (from pH 4.5–5.0 to 5.5–6.0) in chronologi-
cally aged humans, beginning at ≈50 years of age.10,15 An
elevated pH alone can not only compromise epidermal
permeability barrier homeostasis (the primary life-
enabling function of the skin in a desiccating terrestrial
environment),16 but also increases the activity of kallik-
reins, which directly destroy epidermal structure, while
also activating the protease-activated receptor 2, leading
to inflammation and pruritus.17 Chronologically aged
humans also often suffer from intractable pruritus, particu-
larly in low humidity environments, which can provoke
scratching, further disrupting the epidermal permeability
barrier, in turn, exacerbating downstream inflammation
(Figure 1). Prior studies have shown that the defective
epidermal permeability barrier function in chronologically
aged humans and mice stimulates the continuous produc-
tion and release of epidermal cytokines, ultimately resulting
in elevations in circulating cytokines.18,19
In considering chronologically aged versus young skin,
cytokine production in the latter helps to restore permeabil-
ity barrier homeostasis.20,21 But because normal barrier
function can never be achieved in chronologically aged
human skin due to defective acidification and reduced
lipid production,15,22,23 a prolonged release of epidermal
cytokines continues unabated in a futile attempt to restore
normal barrier function. We hypothesized first, that when
sustained over time, such elevations in cutaneous cytokines
could eventually leak into circulation, either contributing or
accounting for the systemic inflammation. In support of the
hypothesis that chronic aging-associated alterations in epi-
dermal function can account for elevations in circulating
Figure 1 Schematic diagram: pathogenic role of epidermal dysfunction in inflam-
maging and its associated disorders in the elderly. Due to reductions in epidermal
lipid production, filaggrin and NHE1/sPLA2 expression, aged humans display multi-
ple functional abnormalities in the epidermis, including delayed permeability barrier
recovery, reduced stratum corneum hydration and elevated stratum corneum pH,
which all can provoke cutaneous inflammation. In turn, cutaneous inflammation can
also induce pruritus, leading to further barrier disruption because of scratching.
Because of skin’s vast size, persistent cutaneous inflammation can induce sustained
elevation in cytokine levels in the circulation, consequently leading to the develop-
ment of inflammaging-associated disorders.
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levels of inflammatory cytokines, i.e. “inflammaging”, we
recently showed that otherwise normal, chronologically
aged mice displayed elevations in both cutaneous and cir-
culating levels of cytokines that parallel chronic aging-
associated abnormalities in epidermal function.18
Moreover, in aged mice, the increase in serum cytokine
levels occurred likely independent of T cell involvement,
because disruption of the epidermal permeability barrier in
athymic mice induced a comparable increase in circulating
levels of inflammatory cytokines to that in normal mice.18
Conversely, correction of epidermal function in chronolo-
gically aged mice reduced both cutaneous and circulating
levels of cytokines.18 Consistent with these findings in
chronologically aged mice, a pilot study in aged humans
(58 to 95 years old without skin diseases) also demonstrated
that correction of epidermal function by repeated topical
applications of an emollient, previously shown to enhance
epidermal function in normal humans, reduced circulating
levels of IL-1β, IL-6 and TNFα.19 Together, this evidence
suggests a pathogenic role for epidermal keratinocytes, and
possibly dermal fibroblasts and/or subcutaneous tissues, in
chronic aging-associated systemic inflammation. Moreover,
the fact that improving epidermal function alone lowered
circulating cytokine levels unlikely supports the primary
role of other organs or tissues, including adipose tissue, in
the pathogenesis of “inflammaging”. Finally, because these
cytokines have been linked to the development of aging-
associated disorders,1–6 we speculate further that exposure
of skin to additional exogenous stressors, such as a reduced
ambient humidity or to excessive psychological stress, both
of which can provoke and exacerbate epidermal permeabil-
ity abnormality and inflammation, could accelerate
the development of inflammaging-associated disorders
(Figure 1).
Taken together, this evidence suggests that strategies
which enhance epidermal function in aged skin could
reduce circulating levels of inflammatory cytokines, sug-
gesting the potential utility of such corrective approaches
as a strategy to prevent and/or mitigate chronic aging-
associated disorders. Yet, further studies are needed to
confirm that skin-derived “inflammaging” provoke the
downstream development of these disorders.
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